Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antitoagulants].

M-M Samama1, G Gerotziafas

  • 1Service d'hématologie Biologique, Hôtel-Dieu, place du Parvis Notre-Dame, F 75181 Paris Cedex 04. mmsamama@aol.com

Annales Pharmaceutiques Francaises
|April 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation.

The journal of nutrition, health & aging·2018
Same author

[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].

Journal des maladies vasculaires·2014
Same author

Prevention and treatment of venous thromboembolism--International Consensus Statement.

International angiology : a journal of the International Union of Angiology·2014
Same author

Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Pro- and anti-angiogenic agents.

Journal des maladies vasculaires·2012
Same journal

No evidence of significant natural environmental exposure to arsenic for Napoleon I on the island of Saint Helena (1815-1821).

Annales pharmaceutiques francaises·2026
Same journal

EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL TISSUE: AN INTERDISCIPLINARY EVIDENCE MAPPING - SCOPING REVIEW.

Annales pharmaceutiques francaises·2026
Same journal

Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

Annales pharmaceutiques francaises·2026
Same journal

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening.

Annales pharmaceutiques francaises·2026
Same journal

Mechanistic and thermodynamic evaluation of sodium citrate-mediated hydrotropism for the biopharmaceutical optimization of BCS Class II drug atorvastatin calcium.

Annales pharmaceutiques francaises·2026
Same journal

Future trends and the role of artificial intelligence in pharmaceutical project management.

Annales pharmaceutiques francaises·2026
See all related articles

New anticoagulant drugs target specific factors in blood clotting, offering improved safety and administration options. Atrial fibrillation is a key area where these novel agents address a significant unmet medical need.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Medical Science

Background:

  • Traditional anticoagulants like vitamin K antagonists and heparins have limitations.
  • Newer anticoagulant agents exhibit enhanced specificity and targeted action within the coagulation cascade.

Discussion:

  • Novel anticoagulants function directly or indirectly, with varying dependence on antithrombin.
  • Key characteristics include target specificity, administration routes (parenteral/oral), pharmacokinetics, and clearance mechanisms (renal/hepatic).
  • Safety profiles involve bleeding risks and potential organ-specific intolerances, necessitating consideration of antidotes and cost.

Key Insights:

  • Fondaparinux is approved for orthopedic surgery, venous thromboembolism treatment, and prophylaxis in medical patients.

Related Experiment Videos

  • Atrial fibrillation represents a primary indication for these advanced anticoagulants due to a growing patient population.
  • The development of specific antidotes and cost-effectiveness remain crucial factors for widespread adoption.

    • Outlook:

    • Continued research into novel anticoagulants will likely focus on optimizing efficacy and safety profiles.
    • Expanding indications for these targeted therapies, particularly in managing atrial fibrillation, is anticipated.
    • The evolving landscape of anticoagulation therapy necessitates ongoing evaluation of new agents for clinical utility and patient benefit.